依降钙素(Elcatonin) - 药物靶点：CALCR_在研适应症：家族性佩吉特氏病，高钙血症，骨质疏松症_专利_临床

概要

基本信息

药物类型

合成多肽

别名

Elcatonin (JP17/INN)

+ [7]

靶点

CALCR

作用机制

CALCR抑制剂(降钙素受体抑制剂)

治疗领域

在研适应症

非在研适应症

原研机构

在研机构

非在研机构

Asahi Kasei Pharma Corp.

最高研发阶段批准上市

首次获批日期

日本 (1982-06-15),

骨质疏松症

最高研发阶段(中国)批准上市

特殊审评孤儿药 (美国)

登录后查看时间轴

结构/序列

分子式C148H244N42O47

InChIKeyDDPFHDCZUJFNAT-PZPWKVFESA-N

CAS号60731-46-6

Sequence Code 1000323

来源: *****

关联

2

项与依降钙素相关的临床试验

ChiCTR-IPR-14005501

/ Recruiting临床4期IIT

Evaluate the effectiveness and safety of elcatonin in the treatment of osteoporosis with lumbar canal stenosis: a multicenter, double-minded, randomized, placebo cnotrolled clinical study

开始日期2014-11-15

申办/合作机构-

NCT01623622

/ Completed临床2期

A Phase 2 Study of HC-58 in Patients With Severe Upper Limb Hemiplegia After Stroke

The purpose of this study is to investigate the efficacy and safety of HC-58 in patients with severe upper limb hemiplegia following stroke.

开始日期2012-07-01

申办/合作机构

Asahi Kasei Pharma Corp.

100 项与依降钙素相关的临床结果

登录后查看更多信息

100 项与依降钙素相关的转化医学

登录后查看更多信息

100 项与依降钙素相关的专利（医药）

登录后查看更多信息

149

项与依降钙素相关的文献（医药）

2023-04-01·International Journal of Surgery Case Reports

A case report of effective intra-articular elcatonin administration in a patient with osteonecrosis of the lunate

作者: Nagai, Takashi ; Inagaki, Katsunori ; Ikeda, Jun ; Kawasaki, Keikichi ; Tomita, Kazunari ; Kubo, Kazutoshi

INTRODUCTION AND IMPORTANCEAlthough corticosteroids are effective for bronchial asthma, they are associated with various side effects, such as osteonecrosis of the femoral head and tibial condyle and osteoporosis. Here, we report a patient who was on corticosteroids for a long period of time due to severe asthma, which was thought to have led to lunate osteonecrosis of both wrist joints. Calcitonin (elcatonin), an osteoporosis drug, was administered to the wrist joint.CASE PRESENTATIONAllergy to anesthetics and various non-steroidal anti-inflammatory drugs (NSAIDs) made surgical treatment not possible and pain control difficult. In addition, pain in the wrist joint interfered with activities of daily living (ADLs). When calcitonin was administered intra-articularly into the wrist joint, the pain in the wrist joint was relieved and ADLs were improved. However, the pain-suppressing effect lasted only 1 week, and pain returned to the original state by the second week after treatment. Repeated injections were necessary every 2 weeks.CLINICAL DISCUSSIONThis is the first report of the effectiveness of intra-articular calcitonin in a patient with osteonecrosis of the lunate. This treatment may be applicable to patients with allergies to anesthesia and NSAIDs.CONCLUSIONIn the present case, calcitonin administered intra-articularly to the wrist appeared to be effective in pain control for steroid-induced lunate osteonecrosis.

2023-01-01·BioMed Research International

Retracted: Impact of Alendronate Sodium plus Elcatonin on Postoperative Bone Pain in Patients with Osteoporotic Fractures

作者: International, BioMed Research

[This retracts the article DOI: 10.1155/2022/1213278.].

2022-07-01·International Journal of Hematology

Diffuse 18F-fluorodeoxyglucose uptake in the bone marrow of an elderly man with B-cell lymphoma

Letter

作者: Sakata, Etsuro ; Notohara, Kenji ; Nakatani, Koya ; Ueda, Yasunori ; Saito, Kenki

An 89-yr-old man with a history of right lung adenocarcinoma, left lung squamous cell carcinoma, and penile squamous cell carcinoma presented with lower back pain persisting for 1 mo and general pain and weakness in both lower limbs persisting for 10 days.A bone marrow biopsy revealed a monotonous increase in small lymphocytes with pale cytoplasm and CD20 positivity.To mitigate acute kidney injury with hypercalcemia, treatment with hydration, elcatonin, and zoledronic acid was initiated.Subsequently, rituximab and a reduced dose of THP-COP therapy (cyclophosphamide, pirarubicin, vincristine, and prednisolone) were started.The patient's renal function improved rapidly with the above treatment.Reduction in bone pain also improved his ability to perform activities of daily living.The soluble IL-2 receptor level after the second course of rituximab and THP-COP therapy was 380 U/mL, indicating dramatic improvement in the patient's condition.

100 项与依降钙素相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D03287	依降钙素	H05BA04	DB13742

研发状态

批准上市

10 条最早获批的记录,

登录

后查看更多信息

适应症	国家/地区	公司	日期
家族性佩吉特氏病	日本	Asahi Kasei Corp.	2006-02-07
高钙血症	中国	山东绿叶制药有限公司	2000-01-01
骨质疏松症	日本	Asahi Kasei Corp.	1982-06-15

未上市

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
偏瘫	临床1期	日本	Asahi Kasei Pharma Corp.	2012-07-01
脑卒中	临床1期	日本	Asahi Kasei Pharma Corp.	2012-07-01

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


ASN2018	N/A	骨质疏松症	-	Elcatonin	餘簾製鏇淵夢製獵襯醖(壓築餘範壓廠窪餘顧醖) = 壓鬱衊夢築夢膚夢醖顧壓壓淵製糧夢簾積艱醖 (願觸選膚廠壓選淵鏇衊 )	不佳	2018-10-23
				Elcatonin (Control Group)	餘簾製鏇淵夢製獵襯醖(壓築餘範壓廠窪餘顧醖) = 壓簾膚鹹積襯餘繭製顧壓壓淵製糧夢簾積艱醖 (願觸選膚廠壓選淵鏇衊 )